- Home
- ABTS vs PPBT Comparison
ABTS vs PPBT Comparison
Compare ABTS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.24
HOLD
Current Price
$1.50
Company Overview
Basic Information| Metric | ABTS | PPBT |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 2.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ABTS | PPBT |
|---|---|---|
| Price | $1.24 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 32.8K | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.41 |
| 52 Week High | $10.86 | $5.18 |
Technical Indicators
Market Signals| Indicator | ABTS | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 41.84 |
| Support Level | $1.02 | $1.39 |
| Resistance Level | $1.56 | $1.85 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 31.11 | 27.36 |
Price Performance
Historical Comparison ABTS
PPBT
About ABTS Abits Group Inc
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.